comparemela.com

Latest Breaking News On - Grant pickering - Page 1 : comparemela.com

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 2,616 Shares

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CEO Grant Pickering sold 2,616 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $72.06, for a total transaction of $188,508.96. Following the transaction, the chief executive officer now owns 144,746 shares in the company, valued […]

Switzerland
Arizona
United-states
Swiss
Keybank-national-association
Swiss-national-bank
Groupa-streptococcus
Needham-company
Barclays-plc
Nasdaq
Vaxcyte-inc

Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $1,041,450.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $69.43, for a total transaction of $1,041,450.00. Following the completion of the sale, the chief executive officer now directly owns 477,847 shares […]

Wellington
New-zealand-general
New-zealand
United-states
America
Nasdaq
Allspring-global-investments-holdings
Cantor-fitzgerald
Mutual-of-america-capital-management
Groupa-streptococcus
Needham-company

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 15,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total value of $928,800.00. Following the completion of the sale, the chief executive officer now directly owns 477,847 shares of […]

United-states
America
Westfield-capital-management-co
Groupa-streptococcus
Norges-bank
Vaxcyte-inc
Securities-exchange-commission
Needham-company
Cantor-fitzgerald
First-turn-management
Eventide-asset-management

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states
Janet-graesser
Jennifer-zibuda
Drug-administration
Nasdaq
Groupa-strep
Data-monitoring-committee
Vaxcyte-inc
Exchange-commission
Company-potential-pneumococcal-conjugate-vaccine
Sutro-biopharma-inc
Corporate-communications

vimarsana © 2020. All Rights Reserved.